Objectives: To re-evaluate serum samples from our 2007 cohort of patients with single episode isolated ON (SION), recurrent isolated ON (RION), chronic relapsing inflammatory optic neuropathy (CRION), multiple sclerosis-associated ON (MSON) and neuro-myelitis optica (NMO).
Introduction
In 2010 we reported the prevalence of NMO-IgG1in a cohort of patients with optic neuropathies in this journal [1] . NMO-IgG has subsequently been found to be identical to aquaporin-4 IgG (AQP4-IgG). Subsequent developments have increased the sensitivity and specificity of the AQP4-IgG test [2] [2; 3] . In addition, a relevant [4] auto-antibody was re-discovered which targets myelinoligodendrocyte glycoprotein (MOG) [5; 6] tmp [6] . Previously, we identified a subset of relapsing optic neuritis in which discrete acute attacks occur (recurrent isolated optic neuritis, RION); these cases resemble MS or NMO but without supporting evidence for either. This phenotype differs from the previously described chronic relapsing inflammatory optic neuropathy (CRION) [7] characterised by corticosteroid dependence or tendency to early relapse upon withdrawal of corticosteroids. In addition, there is emerging cross-sectional data that patients with both RION and CRION may be seropositive for MOG antibodies [8] [9] [10] [8] [9] [10] [11] tmp . The clinical phenotype of MOG-ON is heterogeneous [12] [13] [14] . The need for immunosuppression in patients with CRION strongly suggested an autoimmune pathology [15] .
In this study we revisited our original cohort [1] around 10 years later in order to investigate how the clinical diagnosis changed over time. Samples with remaining serum (103/114) were reanalysed for AQP4-IgG and MOG-IgG1 with state of the art live cell based assays (CBA) [6] .
Patients and Methods
The clinical notes of 114 patients presenting with unilateral or bilateral isolated ON who had originally been recruited between November 1995 and September 2007 [1] were reviewed in 2017.
The study was approved by the local and national ethics committees. Snellen visual acuities (VA) were converted to digital notation as described [16] . Patients were classified exactly as in our original report [1] according to clinical criteria and response to treatment into one of five inflammatory optic neuropathies: multiple sclerosis associated optic neuritis (MSON), singleepisode isolated ON (SION), recurrent isolated ON (RION) CRION or NMO-ON [17] .
Blood samples
Aliquots of all serum samples were stored at -80°C. The samples were coded and send to the respective laboratories for analysis. Serum samples had been tested originally for NMOIgG1antibodies at the Mayo Clinic laboratories [2] . In 2015 they were re-tested for MOG-IgG1 at the Oxford Autoimmune Neurology Diagnostic Laboratory as described [9] .
Serum was available from 103/114 (91.4%) of the original samples, including all the AQP4 seropositive samples; the remaining samples were consumed in previous studies. We have indicated In the table how many samples were available for each test at each time point and for each clinical subgroup. There were 30 missing samples for testing for MOG-IgG1.
Cerebrospinal fluid (CSF) oligoclonal bands were determined using 2-4 µL of sample for isoelectric focusing (IEF) on agarose gels and quality control in the London laboratory as described [18] .
Serum samples were also used to quantify protein biomarkers which have been related to astrocytic damage in NMO [19; 20] , glial fibrillary acidic protein (GFAP) and S100B using in-house developed ELISAs [21; 22] . Finally, neurofilament protein, a biomarker for neurodegeneration [23] , was quantified by in-house ELISA [24] .
Data analysis
Data analysis was performed using SAS (V9.4). Data distribution was non-Gaussian and therefore the median and interquartile ranges are shown. Categorical data were compared using the Chisquare test; continuous data using the Kruskal-Wallis test. Correlation analysis was performed using Spearman's R. A p-value of 0.05 was accepted as significant. All tests were two-sided. Table 2 summarises the updated classification of our patient cohort which incorporates AQP4-IgG and MOG-IgG1 seropositivity. Two cases from the previous classification were excluded, one of whom had a perioptic nerve sheath meningioma and the second a progressive rather than relapsing optic neuropathy. By definition in the new group, MOG-ON only consists of patients (n=11) who were tested seropositive for MOG-IgG1. The NMO-ON group increased in numbers from 9 to 19. All other groups were reduced in numbers, MSON by 2, SION by 6, RION by 5 and CRION by 7. 12 RION and 12 CRION patients remain without known auto-antibody status (missing samples for MOG-IgG in 8, see Table 1 ).
Results

In
New auto-antibody related classification
There is a female predominance in all groups, greatest for RION (75%) and MOG-ON (73%), lowest for NMO (63%). There was a trend for MSON to be the youngest (33 years) and the SION and CRION to be the eldest (44 years). The age difference between groups did however not statistically significance due to small numbers and the large IQR range (p=0.18).
VA at onset (p=0.08) or at follow-up(p=0.19) did not differ between groups. Finally, the number of There was no significant difference in serum NfH, GFAP or S100B levels between the groups (Table 3 ). The highest individual serum GFAP levels were however seen in patients with NMO.
Interestingly one patient who was classified clinically as NMO, but was seronegative both for NMO- 
Discussion
The long term follow-up (up to 33 years) n patients presenting with different forms of optic neuritis [1] showed an increase in the autoantibody seropositivity rate from 9/114 (8%) to 26 (23%). neuritis has previously been reported [25] . Many more cases have since been recognised and importantly treatment with corticosteroids stopped seizures [25] [26] [27] [28] [29] [30] .
These results show clearly that the analytical sensitivity of the laboratory autoantibody tests has improved [1] . Importantly all patients with NMO were seronegative for MOG-IgG1 and the diagnosis of NMO remained unchanged at an averaged 10 year follow-up. The technical improvements A progressive optic neuropathy was eventually diagnosed in two cases who were both seronegative for AQP4-and MOG-IgG. In one case this was due to a perioptic meningioma which was not visible on the initial dedicated orbital MRI sequences. In the other patient the disease course resembled a hereditary mitochondrial optic neuropathy, although neither genetic testing nor a muscle biopsy confirmed this. Nonetheless, when the course becomes progressive rather than relapsing, this raises concerns about either compression due to neoplasm or a neurodegenerative mechanism.
Compared to the recent literature, the seropositivity rate for MOG-IgG in patients with CRION in our cohort (25%) is less than the 67-100% seropositivity rate reported by others [4; 11; 44] [4] .
Differences in study cohorts may be responsible; one was primarily paediatric (104 children, 7 adults) [4] . In a South Korean cohort, 11/12 (92%) of patients initially classified as CRION were seropositive for MOG-IgG [11] and perineural enhancement of the optic nerve in 11/17 patients with MOG-ON [11] . We have observed similar findings in new MOG-ON cases. Likewise the Chinese CRION cohort shares similarities with present cohort regarding the poor visual outcome and MRI features, but has an equal gender balance, rather then the female predominance apparent in our CRION cohort [44] . Future studies should address the diagnostic specificity and sensitivity of this radiologic finding [11] in order to guide development of future diagnostic criteria.
One limitation of this study was the inability to retest 11 patients for AQP4-IgG as there was insufficient serum. MOG-IgG1 could not be assessed in 30 patients, 18 of these had MSON, but this could be a contributing factor to the lower 25% MOG-ON prevalence rate. Likewise we cannot exclude that MOG-IgG is less stable than AQP4-IgG at -80C storage. Another limitation was that recruitment pre-dated the availability of OCT in clinical practice and we were not able to investigate previously observed associations of the antibody status and patterns of retinal layer swelling and atrophy [16] . An important shortcoming of present study is that MRI sequences used when we started to recruit patients with CRION over two decades ago did not permit for imaging at the same level of detail as contemporary sequences. Having recognised these early difficulties with orbital MRI the Queen Square team has contributed to improving the situation by implementation of dedicated sequences. One of the reasons in doing so was the original description of a distinct optic nerve lesion pattern in NMO-ON compared to MSON [45] . Consequently, international consensus recommendations have been made regarding a dedicated MRI protocol for the investigation of optic neuritis [16] . Future studies should make use of such a consensus investigation protocol in order to further elucidate the specificity of MRI patterns in different forms of ON.
In conclusion, the clinical phenotype of optic neuritis should continue to guide the clinical management. In patients with relapsing optic neuritis presence of AQP4-IgG and MOG-IgG renders a diagnosis of MS unlikely, and suggests that immunosuppression should be considered instead of other MS disease modifying treatments, although this recommendation remains based on expert opinion and not high levels of scientific evidence. There is a need for further research to identify the pathophysiology of CRION as many patients with presumed autoimmune pathology remain seronegative for currently known autoimmune targets. There is also a need for future multicentre treatment trials in patients with CRION, NMO-ON and MOG-ON which, because there are no published randomized clinical trials to inform treatment, and all are rare diseases requiring a collaborative network approach.
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